Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pneumonia II: Pathophysiology

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:

Pneumonia I: Introduction

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...

Pneumonia V: Nursing management and Prevention

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....

Pneumonia IV: Management

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:

Pneumonia III: Complications and Assessment

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:

Pulmonary Tuberculosis IV

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Alpha-1 Antitrypsin Replacement Improves Walking Capacity in Subjects With Severe Deficiency.

Respiratory care·2026

Same author

Sarcopenia and Comorbidity Burden Independently Predict Cough Impairment in Hospitalized Patients: A Cross-Sectional Study.

Journal of clinical medicine·2026

Same author

Oxidative Stress Biomarkers in Silicosis: A Systematic Review.

Diseases (Basel, Switzerland)·2026

Same author

Multi-omics to study chronic respiratory diseases and viral infections.

European respiratory review : an official journal of the European Respiratory Society·2026

Same author

GDF11: A promising new drug target for pulmonary fibrosis?

Molecular therapy : the journal of the American Society of Gene Therapy·2025

Same author

A rare case of sudden blindness following mepolizumab withdrawal in EGPA.

Current medical research and opinion·2025

Search research articles

Related Experiment Video

Updated: Jun 25, 2025

Vaccinia Virus Infection & Temporal Analysis of Virus Gene Expression: Part 3

Vaccinia Virus Infection & Temporal Analysis of Virus Gene Expression: Part 3

Published on: April 13, 2009

Poxviridae Pneumonia.

Francesco Nucera¹, Letterio Bonina², Antonino Cipolla³

¹Pneumologia, Dipartimento di Scienze Biomediche, Odontoiatriche e delle Immagini Morfologiche e Funzionali (BIOMORF), Università degli Studi di Messina, Messina, Italy.

Advances in Experimental Medicine and Biology

|May 27, 2024

Summary

Poxviridae viruses, including smallpox and MPXV, can cause severe pneumonia. Current treatments focus on supportive care, antivirals like tecovirimab, and FDA-approved vaccines for prevention.

Keywords:

Cowpox MPXV Smallpox Vaccinia Variola

More Related Videos

Vaccinia Virus Infection & Temporal Analysis of Virus Gene Expression: Part 2

Vaccinia Virus Infection & Temporal Analysis of Virus Gene Expression: Part 2

Published on: April 10, 2009

Vaccinia Virus Infection & Temporal Analysis of Virus Gene Expression: Part 1

Vaccinia Virus Infection & Temporal Analysis of Virus Gene Expression: Part 1

Published on: April 8, 2009

Related Experiment Videos

Last Updated: Jun 25, 2025

Vaccinia Virus Infection & Temporal Analysis of Virus Gene Expression: Part 3

Vaccinia Virus Infection & Temporal Analysis of Virus Gene Expression: Part 3

Published on: April 13, 2009

Vaccinia Virus Infection & Temporal Analysis of Virus Gene Expression: Part 2

Vaccinia Virus Infection & Temporal Analysis of Virus Gene Expression: Part 2

Published on: April 10, 2009

Vaccinia Virus Infection & Temporal Analysis of Virus Gene Expression: Part 1

Vaccinia Virus Infection & Temporal Analysis of Virus Gene Expression: Part 1

Published on: April 8, 2009

Area of Science:

Virology
Infectious Diseases
Pulmonology

Background:

Poxviridae viruses can cause severe pneumonia in humans, historically linked to variola virus (smallpox) and currently relevant with monkeypox virus (MPXV).
Pneumonia presents with potential complications like acute respiratory distress syndrome (ARDS) and death, particularly in immunocompromised individuals.
Pathophysiology involves direct viral damage and hyperinflammatory responses (cytokine storm), with viral immune evasion mechanisms also described.

Purpose of the Study:

To review the clinical presentation, pathophysiology, and management of Poxviridae-associated pneumonia.
To highlight the significance of Poxviridae pneumonia as a potential biological threat and public health concern.
To summarize current and emerging therapeutic and prophylactic strategies.

Main Methods:

Literature review of Poxviridae infections and pneumonia.
Analysis of clinical case reports and animal model studies.
Summary of FDA-approved treatments and vaccines.

Main Results:

Poxviridae pneumonia can be severe, with variola virus historically causing significant mortality and MPXV posing a current risk.
Animal models suggest direct epithelial damage and hyperinflammation contribute to disease severity.
Antiviral drugs (tecovirimat, cidofovir, brincidofovir) and vaccines (JYNNEOS, ACAM2000) are available for treatment and prevention.

Conclusions:

Poxviridae pneumonia requires careful supportive care and targeted antiviral therapy.
Vaccination remains a critical tool for preventing severe disease and managing outbreaks.
Continued research into pathophysiology and treatment is essential for addressing this viral threat.